- HOME
- Products & Services
- Business Collaboration Agreement for exploring Entry into Nucleic Acid Drug CDMO Business
-
Custom DNA/RNA Systhesis
-
Next Generation Sequencing
- Next Generation Sequencing
-
Guide to select the best application for your purpose
- Guide to select the best application for your purpose
- Human genome sequencing
- Genome re-sequencing (other than Human)
- Microbial genome sequencing
- Small scale sequencing (NGS Petit)
- GRAS-Di
- Repeat motif mining
- Gene expression analysis (for organisms with a reference sequence available)
- Iso-Seq analysis
- De novo transcriptome sequencing
- Small RNA-Seq analysis
- Microbial community analysis
- Shotgun metagenome sequencing
- Metatranscriptome sequencing
- ChIP-Seq analysis
- CRISPR screening analysis
- Illumina amplicon sequencing
- PacBio amplicon sequencing
- Standard pipeline analysis
- Custom analysis
- Gene analysis from a pathological specimen (option)
- Sequencer type and sequencing principle
- Required amount of sample
- How to order
- Scientific Publications
-
Custom DNA Sequencing
-
Custom DNA Microarray
-
Protein Related Service
-
Research Support
-
Laboratory Items
Business Collaboration Agreement for exploring Entry into Nucleic Acid Drug CDMO Business
| Business Collaboration Agreement for exploring Entry into Nucleic Acid Drug CDMO Business July 12th, 2024 We are pleased to announce that Hokkaido System Science Co., Ltd. (HSS), having a headquarters in Sapporo, Hokkaido (CEO: Yukio Mizutani) has signed a business collaboration agreement with Mitsubishi Gas Chemical Company, Inc. (MGC), having a headquarters in Chiyoda-ku, Tokyo (President: Masashi Fujii) to jointly explore entry into nucleic acid drug CDMO (Contract Development and Manufacturing Organization) business. HSS has engaged in synthesis and sales of nucleic acids for research use for more than 30 years. Based on such accumulated know-how about nucleic acid synthesis, and together with MGC’s analytical technology and knowledge of Good Manufacturing Practice (GMP), we will aim to launch a nucleic acid drug CDMO business to provide solutions for stakeholders including academic researchers.
|
|
| Download the PDF file. | |